{"id":"NCT02732639","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)","officialTitle":"Open-label, Multicenter, Trial Evaluating Efficacy and Safety of Peginterferon Alfa-2a (PEGASYSÂ®) in Patients With Chronic Hepatitis D (CHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2016-04-08","resultsPosted":"2016-08-26","lastUpdate":"2016-08-26"},"enrollment":31,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis D, Chronic"],"interventions":[{"type":"DRUG","name":"Pegylated Interferon (PEG-IFN) alfa-2a","otherNames":["PEGASYS"]}],"arms":[{"label":"Pegylated Interferon (PEG-IFN) alfa-2a","type":"EXPERIMENTAL"}],"summary":"This study evaluated the efficacy and safety of 48-week treatment with pegylated interferon (PEG-IFN) alfa-2a (Pegasys) monotherapy in participants with chronic hepatitis D (CHD). Treatment was followed by 24 weeks of treatment-free follow-up.","primaryOutcome":{"measure":"Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 72","timeFrame":"At Week 72","effectByArm":[{"arm":"Pegylated Interferon (PEG-IFN) Alfa-2a","deltaMin":54.84,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":7,"countries":["Romania"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":[]}}